Tisento Therapeutics

Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD. For more information, please visit www.nexotx.com.

https://www.nexotx.com/

11-50 employees

Growth Trajectory

Nexo Therapeutics is poised for growth through continued development of small-molecule therapies and pipeline expansion, supported by their $60 million Series A financing. The strategic collaboration with The University of Texas MD Anderson Cancer Center signals a commitment to market expansion and innovation in covalent ligand discovery and chemical biology. Their focus on intractable cancer targets positions them to address unmet needs in the oncology market.

Technical Challenges

Identifying and validating quality ligands for intractable targets.

Gaining a better understanding of the pharmacology of discovered molecules.

Scaling biochemical and in-cell proteomics for high-throughput screening.

Integrating the drug discovery platform with translational research platforms.

Tech Stack

Team Size

Key Risks

The challenge of identifying and validating quality ligands for intractable targets may slow down drug discovery.

Limited understanding of the pharmacology of newly discovered molecules could pose risks in drug development.

Market competition from companies targeting similar cancer indications may impact market share.

Regulatory hurdles and clinical trial failures could delay or halt the development of novel therapies.

Opportunities

Leverage the unique INFINI-T and CODON platforms to create a diverse pipeline of novel cancer therapies.

Expand collaboration with MD Anderson to accelerate drug discovery and translational research.

Capitalize on the growing market demand for targeted cancer therapies.

Develop new modalities for cancer treatment through covalent ligand discovery and chemical biology.

Address market gaps in intractable cancer targets to gain a competitive advantage.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes